Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
HALO

HALO - Halozyme Therapeutics Inc Stock Price, Fair Value and News

$72.86+2.64 (+3.76%)
Market Closed

86/100

HALO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

86/100

HALO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$103.83

Target 3M

$78.7

Target 6M

$89.57

HALO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

HALO Price Action

Last 7 days

1.6%

Last 30 days

5.7%

Last 90 days

12.7%

Trailing 12 Months

30.1%

HALO RSI Chart

HALO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

HALO Valuation

Market Cap

8.6B

Price/Earnings (Trailing)

14.39

Price/Sales (Trailing)

6.89

EV/EBITDA

10.77

Price/Free Cashflow

14.22

HALO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$103.83

Target 3M

$78.7

Target 6M

$89.57

HALO Fundamentals

HALO Revenue

Revenue (TTM)

1.2B

Rev. Growth (Yr)

22.12%

Rev. Growth (Qtr)

8.76%

HALO Earnings

Earnings (TTM)

595.5M

Earnings Growth (Yr)

27.89%

Earnings Growth (Qtr)

6.09%

HALO Profitability

EBT Margin

60.02%

Return on Equity

118.17%

Return on Assets

26.81%

Free Cashflow Yield

7.03%

HALO Investor Care

Buy Backs (1Y)

7.57%

Diluted EPS (TTM)

4.75

HALO Alerts

  • 1 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20251.1B1.2B1.2B0
2024863.0M873.3M947.4M1.0B
2023705.0M773.7M780.7M829.3M
2022471.6M487.5M580.6M660.1M
2021331.3M412.5M463.0M443.3M
2020164.4M180.5M199.6M267.6M
2019177.9M181.9M202.6M196.0M
2018317.9M319.4M281.2M151.9M
2017133.8M134.2M166.1M316.6M
2016146.7M146.7M146.7M146.7M
2015105.9M120.8M138.1M146.7M
201454.9M58.9M57.5M75.3M
201346.7M53.4M64.1M54.8M
201256.0M40.6M22.9M42.3M
201117.7M37.7M57.2M56.1M
201000013.6M
Get all data in R, Python etc through our Historical Stock Data APIs

About Halozyme Therapeutics Inc

HALO
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
 CEO
 WEBSITEhttps://halozyme.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES393

Halozyme Therapeutics Inc Frequently Asked Questions

HALO is the stock ticker symbol of Halozyme Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Halozyme Therapeutics Inc is 8.57 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check HALO's fair value in chart for subscribers.

The fair value guage provides a quick view whether HALO is over valued or under valued. Whether Halozyme Therapeutics Inc is cheap or expensive depends on the assumptions which impact Halozyme Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HALO.

As of Wed Jan 28 2026, HALO's PE ratio (Price to Earnings) is 14.39 and Price to Sales (PS) ratio is 6.89. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HALO PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Halozyme Therapeutics Inc has provided 0.235 (multiply by 100 for percentage) rate of return.